BioNexus Gene Lab Corp (BGLC) Q4 2022 Annual Earnings
BGLC·Reported May 31, 2024·Before market open
BioNexus Gene Lab Corp reported Q4 2022 revenue of $2.8M. Diluted EPS came in at $-0.11.
Revenue
$2.8M
Diluted EPS
$-0.11
Financial Snapshot
Trailing eight quarters through Q4 2022
Q4 2022 Earnings FAQ
Common questions about BioNexus Gene Lab Corp's Q4 2022 earnings report.
BioNexus Gene Lab Corp (BGLC) reported Q4 2022 earnings on May 31, 2024 before market open.
BioNexus Gene Lab Corp reported revenue of $2.8M and diluted EPS of $-0.11 for Q4 2022.
You can read the 10-K periodic report (0001477932-23-002002) directly on SEC EDGAR. The filing index links above go to sec.gov.